Description: Mitovation's mitochondrial modulation therapy is a platform technology to address multiple markets, and is poised to improve clinical outcomes and reduce costs in the treatment of brain injuries.
Mitovation’s infrared light technology is non-invasive and has a robust safety profile.
Mitovation has filed and been issued multiple patents for its technology in the United States and Internationally.
Mitovation’s device qualifies as a Class II Medical device 510k de novo clearance through the Food and Drug Administration.